30 years of expertise in product development
JONATHAN RUBIN: When you bring a drug to market, you have the potential to affect the lives of many, many people and their families.
ERIN AGUSTINUS: Every single day, through every action that we’re doing, we’re helping patients and we’re bettering their lives.
FRANK MOTTOLA: It all starts and ends with the patients. We develop medications to help very unique situations from migraines to epilepsy to Parkinson’s.
ROY THOMAS: People view this company as their own, not just a company that they work for.
DAWN LOURO: Make everyone feel like they’re able to contribute and make a difference.
FRANK MOTTOLA: It’s about knowing what we could bring next.
FRANK MOTTOLA: 2005 started off like I guess any new company. It was fun, it was exciting, it was new.
DAWN LOURO: We had really reliable platforms and we now have five marketed products.
FRANK MOTTOLA: Which is Oxtellar XR, Trokendi XR, Xadago, Myobloc and Apokyn, and shortly on the market, our ADHD products.
ROY THOMAS: Seeing the impact, not only for the patients but the caregivers, the healthcare providers.
FRANK MOTTOLA: We don’t build quality in on the end here. It is never an afterthought from every batch that we release to every testing that we conduct here in our very own facility.
ROY THOMAS: And that requires a different level of work ethic and attitude. The number one differentiator is the culture that we’ve created.
ERIN AGUSTINUS: Whether marketing, whether finance, all the way up to our CEO, Jack.
JONATHAN RUBIN: There’s a lot of energy and there’s passion for the work.
ROY THOMAS: We really try to understand who people are, their goals and visions, their aspirations, and that has to align with Supernus Pharmaceuticals as well.
FRANK MOTTOLA: As the company did grow from about 30 employees to where we are today, well over 550, some things haven’t changed. Carrying the integrity, the honesty, that has really been ingrained in ourselves as Supernus employees.
DAWN LOURO: We are bigger than we once were but we’re still small in culture and community. We don’t aspire to be big pharmas.
ERIN AGUSTINUS: So, we need to be innovative and we need to be unique in how we can differentiate our products, and that’s what continues to challenge us as individuals and allows us to continue to grow.
ROY THOMAS: We’re a part of building something very special here. There’s no limit as to where you can be in this company.
FRANK MOTTOLA: Fifteen years later, here we are. It’s been a very fun and loving journey. Painful at times, like any growing company, of course, but something I wouldn’t trade for the world.
We are a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Over the last 30 years, we have built an extensive expertise in product development. Initially, we were a stand-alone development organization, then a U.S. subsidiary of Shire plc and, in late 2005, we became Supernus Pharmaceuticals, Inc.
Supernus Mission and Values
Mission: To improve the lives of patients suffering from diseases of the central nervous system (CNS)
We market our products within the United States through our own specialty sales forces. We also seek strategic collaborations with other pharmaceutical companies to license our products outside the United States.
A record of successful products, with more in development
We market Qelbree® (viloxazine) extended-release capsules for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients ages 6 years and older, Trokendi XR® (topiramate) extended-release capsules for the preventive treatment of migraine and the treatment of certain types of epilepsy, Oxtellar XR® (oxcarbazepine) extended-release tablets for the treatment of partial onset seizures, Apokyn® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD) and GOCOVRI® (amantadine) extended release capsules for the treatment of both OFF and dyskinesia in patients with Parkinson’s disease (PD).
Additionally, we market Myobloc® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults, Xadago® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility and Osmolex ER® (amantadine) extended release tablets for the treatment of Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients.
A record of successful products, with more in development:
SPN-830 for hypomobility in Parkinson’s disease »
SPN-820 (NV-5138) for treatment-resistant depression »
SPN-817 for the treatment of certain types of epilepsy »
Shaping the future by focusing on novel treatments
At Supernus, we strive to be a leader in the CNS industry by developing and commercializing new medicines in neurology and psychiatry. Some key elements of our strategy to accomplish this vision are to:
Drive growth and profitability.
Using dedicated sales and marketing resources in the U.S., we will continue to drive the revenue growth of Qelbree®, Trokendi XR®, Oxtellar XR®, Apokyn®, GOCOVRI®, Xadago®, Myobloc® and Osmolex ER®.
Advance product candidates toward commercialization.
Several product candidates in our pipeline are in early-to-late stage clinical testing, and moving toward being commercially available to patients.
Continue to grow our pipeline.
We will continue to evaluate and develop additional CNS product candidates that we believe have significant commercial potential through our internal research and development efforts.
Target strategic business development opportunities.
We are actively exploring a broad range of strategic opportunities. This includes in-licensing products and entering into co-promotion and co-development partnerships for our marketed products and product candidates.